The cytokine Meteorin-like inhibits anti-tumor CD8+ T cell responses by disrupting mitochondrial function

类Meteorin细胞因子通过破坏线粒体功能抑制抗肿瘤CD8+ T细胞反应。

阅读:11
作者:Christopher M Jackson ,Ayush Pant ,Wikum Dinalankara ,John Choi ,Aanchal Jain ,Ryan Nitta ,Eli Yazigi ,Laura Saleh ,Liang Zhao ,Thomas R Nirschl ,Christina M Kochel ,Brandon Hwa-Lin Bergsneider ,Denis Routkevitch ,Kisha Patel ,Kwang Bog Cho ,Stephany Tzeng ,Sarah Y Neshat ,Young-Hoon Kim ,Barbara J Smith ,Maria Cecilia Ramello ,Elena Sotillo ,Xinnan Wang ,Jordan J Green ,Chetan Bettegowda ,Gordon Li ,Henry Brem ,Crystal L Mackall ,Drew M Pardoll ,Charles G Drake ,Luigi Marchionni ,Michael Lim

Abstract

Tumor-infiltrating lymphocyte (TIL) hypofunction contributes to the progression of advanced cancers and is a frequent target of immunotherapy. Emerging evidence indicates that metabolic insufficiency drives T cell hypofunction during tonic stimulation, but the signals that initiate metabolic reprogramming in this context are largely unknown. Here, we found that Meteorin-like (METRNL), a metabolically active cytokine secreted by immune cells in the tumor microenvironment (TME), induced bioenergetic failure of CD8+ T cells. METRNL was secreted by CD8+ T cells during repeated stimulation and acted via both autocrine and paracrine signaling. Mechanistically, METRNL increased E2F-peroxisome proliferator-activated receptor delta (PPARδ) activity, causing mitochondrial depolarization and decreased oxidative phosphorylation, which triggered a compensatory bioenergetic shift to glycolysis. Metrnl ablation or downregulation improved the metabolic fitness of CD8+ T cells and enhanced tumor control in several tumor models, demonstrating the translational potential of targeting the METRNL-E2F-PPARδ pathway to support bioenergetic fitness of CD8+ TILs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。